Mitoxantrone liposome-based MEA regimen for treatment mixed lineage leukemia-rearranged acute myeloid leukemia: a case series.

ABSTRACT:

Background

Acute myeloid leukemia (AML) harboring mixed lineage leukemia (MLL) rearrangement typically presents with high malignancy, poor remission rates, susceptibility to relapse, and a dismal prognosis. For these patients, achieving rapid remission followed by allogeneic hematopoietic stem cell transplantation (allo-HSCT) is an important strategy, underscoring the importance of choosing the initial induction regimen. Mitoxantrone liposome (L-MIT) is a modified drug formulation that enhances anti-tumor activity and reduces toxicity. At present, there is no report on the efficacy and safety of the MEA regimen consisting of L-MIT combined with etoposide and cytarabine in patients with AML with MLL rearrangement.

Case description

We described four patients with

SUBMITTER: Guo H 

PROVIDER: S-EPMC12319592 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature